Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 18/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20715370 | 1.00 | SSTR4 (0.55) | SSTR4SLC6A2SSTR1SSTR2SSTR3 | |
| SCHEMBL21902109 | 1.00 | SSTR4 (0.55) | SSTR4SLC6A2SSTR1SSTR2SSTR3 | |
| SCHEMBL25046589 | 0.89 | SSTR4 (0.49) | SSTR4SLC6A2SSTR1SSTR2SSTR3 | |
| Hydrochloric Acid SCHEMBL29189762 | 0.87 | SSTR4 (0.48) | SSTR4SLC6A2SSTR1SSTR2SSTR3 | |
| SCHEMBL20711876 | 0.84 | SSTR4 (0.55) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL29516296 | 0.84 | SSTR4 (0.55) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL10908504 | 0.82 | SSTR4 (0.53) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL18664465 | 0.81 | SSTR4 (0.52) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL18664463 | 0.81 | SSTR4 (0.52) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL8860932 | 0.81 | SSTR4 (0.52) | SSTR4SSTR1SSTR2SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522596-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2025-03-19 | — | — | EP | claimed |
| CN-119487019-A | Piperazine derivatives for HIV therapy | VIIV保健公司 | 2025-02-18 | — | — | CN | claimed |
| WO-2023218203-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-11-16 | — | — | WO | claimed |
| CN-111601798-B | Bisamide sarcomere activating compounds and uses thereof | 美国安进公司 | 2023-08-11 | — | — | CN | claimed |
| EP-3057964-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2016-08-24 | — | — | EP | claimed |
| WO-2015057659-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | claimed |
| WO-2012024419-A2 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2012-02-23 | — | — | WO | claimed |
| CN-115703765-B | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119487019-A | Piperazine derivatives for HIV therapy | VIIV保健公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024261328-A1 | AMIDE-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2024-12-26 | — | — | WO | disclosed |
| US-20240398784-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024173453-A1 | HETEROARYL-SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS | IDEAYA BIOSCIENCES, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| EP-1803719-A1 | 1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-07-04 | — | — | EP | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | SSTR4 3648/4885SLC6A2 3642/4885SSTR1 3237/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | SSTR4 2007/4885SLC6A2 1343/4885SSTR1 2448/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | SSTR4 3356/4885SLC6A2 3753/4885SSTR1 2542/4885 |
| US-20240398784-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, BRSK2 | SSTR4 4877/4885SLC6A2 1201/4885SSTR1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.